Clinical trials
Non-alcoholic Fatty Liver Disease trials in Canada
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
91 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 2 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 4 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 3 |
| 2014 | 2 |
| 2015 | 8 |
| 2016 | 7 |
| 2017 | 12 |
| 2018 | 3 |
| 2019 | 6 |
| 2020 | 7 |
| 2021 | 11 |
| 2022 | 4 |
| 2023 | 5 |
| 2024 | 7 |
| 2025 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 39 |
| Terminated | 19 |
| Recruiting | 12 |
| Unknown status | 12 |
| Active, not recruiting | 9 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Gilead Sciences | 8 |
| Novo Nordisk A/S | 5 |
| Johane Allard | 4 |
| Merck Sharp & Dohme LLC | 4 |
| Novartis Pharmaceuticals | 4 |
| Pfizer | 4 |
| University of Toronto | 4 |
| Centre hospitalier de l'Université de Montréal (CHUM) | 3 |
| GlaxoSmithKline | 3 |
| McGill University Health Centre/Research Institute of the McGill University Health Centre | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Non-alcoholic Fatty Liver Disease | 91 |
| Fatty Liver | 24 |
| Fibrosis | 12 |
| Diabetes Mellitus, Type 2 | 11 |
| Obesity | 11 |
| Liver Diseases | 9 |
| Liver Cirrhosis | 8 |
| Diabetes Mellitus | 7 |
| Metabolic Syndrome | 7 |
| Cardiovascular Diseases | 6 |
Trials
Showing 1 to 25 of 91. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.